ID   NCI-H3255GR
AC   CVCL_DI55
SY   H3255GR; H3255 GR
DR   Cosmic; 1128246
DR   Wikidata; Q54908038
RX   PubMed=16906227;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI:49668; Gefitinib (ZD1839; Iressa).
CC   Derived from site: Metastatic; Pleural effusion; UBERON=UBERON_0000175.
DI   NCIt; C3512; Lung adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_6831 ! NCI-H3255
SX   Female
AG   47Y
CA   Cancer cell line
DT   Created: 13-07-16; Last updated: 05-10-23; Version: 5
//
RX   PubMed=16906227; DOI=10.1172/JCI28656;
RA   Engelman J.A., Mukohara T., Zejnullahu K., Lifshits E., Borras A.M.,
RA   Gale C.-M., Naumov G.N., Yeap B.Y., Jarrell E., Sun J., Tracy S.,
RA   Zhao X.-J., Heymach J.V., Johnson B.E., Cantley L.C., Janne P.A.;
RT   "Allelic dilution obscures detection of a biologically significant
RT   resistance mutation in EGFR-amplified lung cancer.";
RL   J. Clin. Invest. 116:2695-2706(2006).
//